Table 2 Hematological profile of confirmed CML patients at presentation (n = 251)
Hematological parameters | Total (Median, IQR) | Prechemo treatment (Hydroxyurea) | P value | |
|---|---|---|---|---|
Naïve (Median, IQR) | Treated (Median, IQR) | |||
WBC (x103/µL) | 217.7(155.62–307.4) | 261.2(186.6-349.7) | 188.3(139.3-290.73) | <0.001 |
RBC (x106/µL) | 3.2(2.72–3.6) | 3.05(2.7–3.6) | 3.3(2.72–3.75) | 0.153 |
HGB (g/dl) | 9.3(8.2–11) | 8.9(7.9–10.2) | 9.75(8.33–11.2) | 0.024 |
HCT (%) | 29.05(25.85–33.5) | 28.3(24.3–32.2) | 29.75(26.75–34.4) | 0.024 |
MCV (fL) | 92.85(87.3–97.2) | 92.5(86.9–96.3) | 93.05(88-98.56) | 0.217 |
MCH (pg) | 29.5(27.8–31.4) | 29.1(27.5–30.7) | 29.9(27.97–31.85) | 0.061 |
MCHC (g/dl) | 31.6(30.8–32.6) | 31.6(30.6–32.6) | 31.6(30.9–32.6) | 0.538 |
RDW (%) | 20.8(19.5–23.3) | 20.6(19.4–22.2) | 21.2(19.5–23.4) | 0.304 |
PLT (x103/µL) | 324 (211–499) | 322(211–447) | 324.5(211-508.75) | 0.592 |
MPV (fL) | 8.9 (8.1–9.8) | 8.8 (8.07–9.3) | 9 (8.2–10) | 0.628 |
NE % | 85.75 (78.1-89.77) | 87.4 (80.9–90.3) | 84.3 (77.8–88.4) | 0.001 |
LY % | 4.5 (2.53–7.3) | 3.8 (2.2–6.83) | 5.2 (2.9–7.6) | 0.008 |
MO % | 4.25 (2.8–6.5) | 3.5 (2.5–5.7) | 4.7 (3.07–6.8) | 0.005 |
EO % | 2.3 (1.4–3.85) | 2.4 (1.5–3.6) | 2.3 (1.2–4.05) | 0.557 |
BA % | 1.1 (0.3–3.3) | 0.8 (0.3-2) | 1.4 (0.45–4.7) | 0.002 |
NE # x103/µL | 174.8(111.3-263.6) | 201(137.12–295.6) | 145.25(97.2-241.57) | 0.000 |
LY # x103/µL | 7.85(4.95–14.3) | 7.52(5.1-14.15) | 8.2(4.7–15.3) | 0.975 |
MO # x103/µL | 9.2(4.9-14.12) | 9.1(4.85–13.15) | 9.4(4.97–15.35) | 0.926 |
EO # x103/µL | 5.1(2.7–8.8) | 5.95(3.0-10.23) | 4.1(2.1–8.2) | 0.004 |
BA # x103/µL | 2.39(0.53–6.3) | 2.1(0.5–5.7) | 2.92(0.72–7.5) | 0.083 |